2022
DOI: 10.1186/s12885-022-09615-z
|View full text |Cite
|
Sign up to set email alerts
|

Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study

Abstract: Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-spe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 52 publications
0
3
0
Order By: Relevance
“…Biomarkers could be utilized as stimulus changers or prognostic factors for unique type of therapy, as well as to select the effective type of treatment. KRAS is a predictive biomarker for colorectal cancer; mutations occurring to KRAS in somatic cells are related to low response to anti-EGFR-mediated treatment [ 60 , 61 ]. Likewise, HER2 over-expression in the breast cancer as well as gastric cancer anticipates for stimulus to anti-Her2 drugs such as trastuzumab [ 62 , 63 , 64 , 65 , 66 , 67 ], and over-expression of estrogen receptor anticipates for stimulus to anti-endocrine therapy or treatment such as tamoxifen in breast cancer [ 68 , 69 ].…”
Section: Cancer Biomarkersmentioning
confidence: 99%
“…Biomarkers could be utilized as stimulus changers or prognostic factors for unique type of therapy, as well as to select the effective type of treatment. KRAS is a predictive biomarker for colorectal cancer; mutations occurring to KRAS in somatic cells are related to low response to anti-EGFR-mediated treatment [ 60 , 61 ]. Likewise, HER2 over-expression in the breast cancer as well as gastric cancer anticipates for stimulus to anti-Her2 drugs such as trastuzumab [ 62 , 63 , 64 , 65 , 66 , 67 ], and over-expression of estrogen receptor anticipates for stimulus to anti-endocrine therapy or treatment such as tamoxifen in breast cancer [ 68 , 69 ].…”
Section: Cancer Biomarkersmentioning
confidence: 99%
“…In the past several years, primary tumor sidedness has been recognized as the predictive value of prognosis of colon cancer patients. Right-sidedness was demonstrated to be associated with poor survival in the colon cancer patients with metastasis [4][5][6][7][8], stage III [9], stage II-III microsatellite stable [10], unresectable recurrence [11]. However, the difference between right-sided and left-sided colon cancer in surgical outcome has seldom been reported on and continues to be controversial [12][13][14].…”
Section: Introductionmentioning
confidence: 99%
“…9 Risk of recurrence has been reported to be higher in men than in women, and in people with rectal cancer compared to people with colon cancer. 9,10 Furthermore, the localisation of recurrences also seems to differ per location of the primary tumour, 9,11 and may differ for men and women, 11 implying different underlying mechanisms are involved leading to cancer recurrence.…”
Section: Introductionmentioning
confidence: 99%